Core Insights - Recursion, a clinical stage TechBio company, will be featured in a Lightning Talk at the NVIDIA GTC AI Conference, focusing on the integration of AI, automation, and robotics in drug discovery and development [1][4] Company Overview - Recursion is a leading TechBio company that decodes biology to improve lives, utilizing a platform called Recursion OS to generate one of the largest proprietary biological and chemical datasets [5] - The company operates sophisticated integrated wet and dry labs for AI drug discovery, generating millions of multi-omic data points weekly to enhance the drug discovery process [3][5] - Recursion's operations are supported by its powerful supercomputer, BioHive-2, which facilitates end-to-end improvements in drug discovery, including biological discoveries, precision drug design, and optimized clinical trials [3][5] Collaboration and Technology - Recursion is collaborating with HighRes Biosolutions to develop self-driving, high-throughput labs using advanced automation and orchestration technologies [2] - The collaboration leverages HighRes technologies such as robotic perception and digital twins of laboratory environments, which are essential for creating self-driving laboratories [2] Industry Impact - The advancements in AI and accelerated computing are pushing the boundaries of drug discovery, with NVIDIA's involvement highlighting the transition from concept to reality in Physical AI [4]

Recursion Pharmaceuticals (RXRX) closed at $3.42 in the latest trading session, marking a -8.06% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.69%. Meanwhile, the Dow experienced a rise of 0.47%, and the technology-dominated Nasdaq saw an increase of 0.9%. Prior to today's trading, shares of the biotechnology company had lost 25% lagged the Medical sector's gain of 0.77% and the S&P 500's loss of 1%.Market participants will be closely following the financial resu ...

When artificial intelligence (AI) chip maker NVIDIA Corporation (NVDA) heads for the exit, investors instinctively glance at the door. In its latest 13F filing, the chip giant disclosed that it had completely exited its position in the AI-driven drug developer Recursion Pharmaceuticals (RXRX). At the end of Q3 2025, Nvidia held 7.71 million shares. The stake represented a modest slice of its expansive, meticulously managed AI portfolio. Still, the headline carried weight. Traders pushed the stock down as ...

周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超13%，报3.46美元。消 息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度清仓了Recursion Pharmaceuticals。 来源：智通财经网 ...

智通财经APP获悉，周三，Recursion Pharmaceuticals(RXRX.US)盘前股价暴跌，截至发稿，该股跌超 13%，报3.46美元。消息面上，英伟达(NVDA.US)向美国SEC递交的13F文件显示，其在2025年四季度 清仓了Recursion Pharmaceuticals。 ...

Core Insights - Recursion, a clinical stage TechBio company, will provide business updates and report its fourth quarter and full year 2025 financial results on February 25, 2026, before the market opens [1] - The company will host a live earnings call on the same day at 8:00 am ET, allowing investors and the public to submit questions [2] Company Overview - Recursion is focused on decoding biology to improve lives, utilizing its Recursion OS platform to generate one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, operating at a scale of millions of wet lab experiments weekly [3] - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, with additional offices in Montréal, New York, London, and the Oxford area [4]

Core Insights - Recursion, a clinical stage TechBio company, has granted inducement restricted stock unit (RSU) awards covering 820,431 shares to 17 new employees as part of its 2024 Inducement Equity Incentive Plan [1][2] Group 1: Inducement RSU Awards - The RSU awards will vest 25% on the first quarterly vesting date after one year from the vesting commencement date, followed by 1/16th of the shares on each subsequent quarterly vesting date [2] - The awards are contingent upon the continued employment of the recipients through the vesting dates and are governed by the terms of the 2024 Plan and grant agreements [2] Group 2: Company Overview - Recursion is focused on decoding biology to improve lives, utilizing a platform known as Recursion OS, which generates one of the largest proprietary biological and chemical datasets [3] - The company employs advanced machine-learning algorithms to identify trillions of relationships in biology and chemistry, free from human bias [3] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers globally, integrating technology, biology, and chemistry to advance medicine [3] Group 3: Company Location and Presence - Recursion is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [4] - The company has additional offices in Montréal, New York, London, and the Oxford area [4]

Core Viewpoint - Recursion Pharmaceuticals is experiencing a decline in stock performance, with a notable drop of 17.26% over the past month, which is significantly worse than the broader market indices [1] Financial Performance - The upcoming financial results for Recursion Pharmaceuticals are expected to show an EPS of -$0.28, representing a 47.17% increase compared to the same quarter last year [2] - Revenue is anticipated to reach $25.5 million, reflecting a substantial increase of 460.44% from the prior-year quarter [2] - For the full year, earnings are projected at -$1.59 per share and revenue at $64.62 million, indicating increases of 5.92% and 9.83% respectively from the previous year [3] Analyst Estimates - Recent changes in analyst estimates for Recursion Pharmaceuticals suggest a positive outlook for the business, as positive revisions are often indicative of favorable near-term trends [3][4] - The Zacks Rank system currently rates Recursion Pharmaceuticals as 2 (Buy), indicating a favorable investment outlook [5] Industry Context - Recursion Pharmaceuticals operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 86, placing it in the top 36% of over 250 industries [6] - The Zacks Industry Rank is based on the average Zacks Rank of individual stocks, with top-rated industries historically outperforming lower-rated ones by a factor of 2 to 1 [6]

Core Insights - The article discusses the potential of artificial intelligence (AI) in drug development, highlighting Recursion Pharmaceuticals as a leader in this space [1][2]. Company Overview - Recursion Pharmaceuticals utilizes its platform, Recursion OS, which processes 65 petabytes of chemical and biological data to virtually test drugs [2]. - The company is currently advancing eight drugs in its developmental pipeline, with half already in clinical trials involving real patients [5]. Financial Projections - Analysts project Recursion's revenue to increase from an anticipated $62 million last year to $83 million this year, with a target of $163 million by 2028 as R&D milestone payments from partners are expected to rise [6]. - The current market capitalization of Recursion Pharmaceuticals is $2.1 billion, with a current stock price of $3.98 [7]. Industry Context - The AI-powered drug development industry is expected to grow at an average annual rate of 30% from now until 2034, indicating significant market potential for companies like Recursion [9].

Summary of Key Points from the Conference Call on AI-Driven Drug Discovery (AIDD) Industry Overview - **Industry Focus**: Biotechnology, specifically AI-driven drug discovery (AIDD) in the Asia Pacific region [1] - **Current State**: AIDD is transitioning from pilot projects to commercial reality, with significant growth in partnerships and platform deals [2] Core Insights - **Chemistry Models**: These models are mature and have proven to enhance execution efficiency in drug discovery, leading to faster iteration cycles and improved hit-to-lead conversion rates [10][12] - **Biology Models**: While chemistry models are monetizable, biology models, which influence drug development decisions, are still in the validation phase. Their success hinges on demonstrating human relevance through clinical data [3][11] - **2026 as a Pivotal Year**: A series of clinical and translational readouts expected in 2026 will test the validity of biology models, potentially shifting AIDD from execution support to authoritative decision-making [4][16] Investment Opportunities - **CLARITY Framework**: This framework distinguishes between chemistry-execution platforms, which have proven value, and biology-exposed platforms, which may see a revaluation based on upcoming validation results [5][21] - **Recommended Strategy**: The strategy involves pairing investments in established chemistry platforms with selective exposure to emerging biology-validation platforms [6] Key Developments and Case Studies - **Insilico Medicine**: Positive Phase 2a data for its TNIK inhibitor indicates early validation of AI-driven biology models [23][65] - **Recursion Pharmaceuticals**: REC-4881 shows promise in clinical validation, with additional data expected in 2026 [67] - **Absci**: ABS-201, an AI-designed antibody, is in first-in-human studies, with interim data anticipated in 2H26 [66] Market Dynamics - **China's Role**: China is emerging as a key player in AIDD, leveraging its clinical development infrastructure and rapid adoption of AI tools to enhance drug discovery processes [4][72][77] - **Global Trends**: The biopharmaceutical industry is facing pressures such as patent cliffs and declining R&D ROI, driving the need for innovative tools like AIDD [13][41] Risks and Challenges - **Adoption Barriers**: Organizational frictions, such as data silos and misaligned incentives, may hinder the widespread adoption of AIDD technologies [15][50] - **Validation Risks**: Biology models may fail to demonstrate consistent human relevance, which could impact their adoption and valuation [26][70] Conclusion - **Future Outlook**: The next 18-24 months are critical for AIDD, with multiple programs expected to generate early clinical signals that could validate the efficacy of AI in drug discovery [56][70] - **Investment Implications**: As biology models gain validation, there may be a shift in how AIDD companies capture value, moving towards co-development and downstream economic participation [69][71]